<SUBMISSION>
<ACCESSION-NUMBER>0000891092-03-001752
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20030724
<ITEMS>5
<ITEMS>7
<FILING-DATE>20030728
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>CORNICHE GROUP INC /DE
<CIK>0000320017
<ASSIGNED-SIC>6399
<IRS-NUMBER>222343568
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-10909
<FILM-NUMBER>03806268
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>610 SOUTH INDUSTRIAL BLVD STE 220
<CITY>EULESS
<STATE>TX
<ZIP>76040
<PHONE>8172834250
</BUSINESS-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>FIDELITY MEDICAL INC
<DATE-CHANGED>19951025
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>FIDELITY MEDICAL SERVICES INC
<DATE-CHANGED>19830825
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>e15318_8k.txt
<DESCRIPTION>FORM 8-K
<TEXT>

                       SECURITIES AND EXCHANGE COMMISSION

                              Washington, DC 20549

                                   ----------

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                Date of Report (Date of earliest event reported):
                                  July 24, 2003

                           CORNICHE GROUP INCORPORATED
                           ---------------------------
             (Exact name of registrant as specified in its charter)

                                    Delaware
                                    --------
                 (State or other jurisdiction of incorporation)

       0-10909                                                  22-2343568
--------------------------------------------------------------------------------
Commission File Number                                         IRS Employer
                                                            Identification No.

        330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE, NEW YORK  11747
        ---------------------------------------------------------------
            (Address of principal executive offices)         (Zip Code)

                                  631-574-4955
                                  ------------
                          Registrant's Telephone Number


<PAGE>

ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE

      Corniche  Group  Incorporated  (the  "Company")  issued the press  release
annexed  hereto  announcing  the  change of the  Company's  name to  "Phase  III
Medical,  Inc."  The  name  change  became  effective  upon  the  filing  of the
Certificate of Amendment of Certificate of  Incorporation of the Company annexed
hereto on July 24, 2003.

                                    * * * * *

This Report contains forward-looking statements made pursuant to the safe harbor
provisions   of  the  Private   Securities   Litigation   Reform  Act  of  1995.
Forward-looking  statements  represent  management's  judgment  regarding future
events.  Although  management  believes that the expectations  reflected in such
statements are reasonable,  they give no assurance that such  expectations  will
prove to be correct and you should be aware that  actual  results  could  differ
materially  from those  contained  in the  forward-looking  statements  due to a
number of factors.  These  factors  include  the risk that the  Company  will be
unable to raise capital,  to enter successfully or exploit  opportunities in the
biotech  or  medical  business,  to have  appropriate  personnel,  or the  risks
inherent in any new business  venture or those  detailed in the Company's  other
reports  filed  with  the  Securities  and  Exchange  Commission.   The  Company
undertakes no obligation to update or revise the  information  contained in this
Report whether as a result of new information, future events or circumstances or
otherwise.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

Exhibit 3.1       Certificate of Amendment of Certificate of Incorporation
Exhibit 99.1      Press Release


                                      -2-

<PAGE>

                                    SIGNATURE

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                             CORNICHE GROUP INCORPORATED

                                             By: /s/ Mark Weinreb
                                                 ------------------------
                                                 Mark Weinreb
                                                 President

Dated: July 24, 2003


                                      -3-


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>e15318ex3_1.txt
<DESCRIPTION>CERTIFICATE OF AMENDMENT
<TEXT>

                                                                     Exhibit 3.1

                            CERTIFICATE OF AMENDMENT

                                       OF

                          CERTIFICATE OF INCORPORATION

                                       OF

                           CORNICHE GROUP INCORPORATED

               (Under Section 242 of the General Corporation Law)

      The  undersigned,  being the  President  and  Secretary of Corniche  Group
Incorporated,  a corporation  organized and existing under the laws of the State
of Delaware (the "Corporation"), do hereby amend and certify as follows:

      1. The name of the Corporation is Corniche Group Incorporated.

      2. The Certificate of  Incorporation  of the Corporation is hereby amended
to effect the following  amendments which were set forth in a resolution adopted
by the board of  directors  and  adopted by the  holders  of a  majority  of the
outstanding shares of common stock of the Corporation  entitled to vote thereon,
in  accordance  with the  provisions  of  Section  242 of the  Delaware  General
Corporation  Law: (a) to change the name of the  Corporation and (b) to increase
the number of authorized shares of Common Stock.

      3. To accomplish the first of the foregoing  amendments,  Article First of
the  Certificate  of  Incorporation  is hereby amended to change the name of the
corporation as follows: "The name of the Corporation is PHASE III MEDICAL INC."

      4. To  accomplish  the  second  of the  foregoing  amendments,  the  first
paragraph of Article Fourth of the Certificate of Incorporation,  as amended, is
restated in its entirety as follows :

      FOURTH:  The total number of shares of stock which the  Corporation  shall
have authority to issue is TWO HUNDRED FIFTY FIVE MILLION  (255,000,000)  shares
consisting of (i) Two Hundred Fifty Million (250,000,000) shares of Common Stock
of the par value of $.001 per share and (ii) Five Million  (5,000,000) shares of
Preferred Stock of the par value of $.01 per share.


<PAGE>

      IN WITNESS  WHEREOF,  the undersigned  being a duly elected officer of the
Corporation,  has  executed  this  Certificate  of  Amendment  and  affirms  the
statements herein contained on this 24th day of July, 2003.

                                 CORNICHE GROUP INCORPORATED

                                 By: /s/ Mark Weinreb
                                     -------------------------------------
                                     Mark Weinreb, President and Secretary


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>e15318ex99_1.txt
<DESCRIPTION>PRESS RELEASE
<TEXT>
                                                                    Exhibit 99.1

FOR IMMEDIATE RELEASE

                            Corniche Group Announces
                     Name Change to PHASE III MEDICAL, INC.

Melville,  NY, June 24, 2003.  Corniche Group Incorporated  (OTCBB:  CNGI) today
announced the results of its Annual Meeting of  Shareholders.  The  shareholders
approved its change of the Corporation's  name to "Phase III Medical,  Inc." The
Company believes that Phase III Medical, Inc. is an appropriate name in light of
the new nature of its  business.  The Company has been  focusing on entering the
medical  sector by acquiring  or  participating  in one or more  biotech  and/or
medical companies or technologies,  owning one or more drugs or medical devices,
or  acquiring  rights to one or more of such  drugs or  medical  devices  or the
royalties  therefrom.  It would not be necessary for  stockholders  to surrender
their present Corniche Group stock  certificates as a result of the name change.
The Company has applied to NASDAQ for a new stock symbol.

In addition, the Company's shareholders elected two directors: Mark Weinreb, the
current  President and Chief  Executive  Officer of the Company and Dr. Wayne A.
Marasco,  an Associate  Professor in the Department of Cancer and Immunology and
Aids at the Dana-Farber Cancer Institute and Associate  Professor of Medicine in
the  Department of Medicine,  Harvard  Medical  School.  The  shareholders  also
approved an increase in the number of authorized  shares of the Company's common
stock and adoption of the Company's 2003 Equity Participation Plan.

                                    * * * * *

This  Release  contains  forward-looking  statements  made  pursuant to the safe
harbor provisions of the Private Securities  Litigation Reform Act of 1995, such
as the Company's ability to enter the medical sector or acquire any companies or
technologies.   Forward-looking   statements  represent   management's  judgment
regarding  future events.  Although  management  believes that the  expectations
reflected in such  statements  are  reasonable,  it gives no assurance that such
expectations  will  prove to be  correct  and you  should be aware  that  actual
results  could differ  materially  from those  contained in the  forward-looking
statements due to a number of factors.  These factors include the risks detailed
in the Company's Annual Report on Form 10-K for the year ended December 31, 2002
and other reports filed with the Securities and Exchange Commission.

For further information please contact:

Mark Weinreb, CEO at 631.574.4955

</TEXT>
</DOCUMENT>
</SUBMISSION>
